If you have been reading about peptide research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Protein complex purification === Complexes of interacting proteins may also be purified using the SBP-Tag because elution with biotin permits recovery under conditions in which desired complexes remain associated. For example, the Condensin Complex was purified by Kim et al. [2010] and complexes with the TAZ transcriptional co-activator were purified by Zhang et al. [2009]. The SBP-Tag has also been incorporated into several Tandem Affinity Purification (TAP) systems in which successive purification steps are utilized with multiple tags, for example GFP fusion proteins and BTK-protein complexes were purified using a TAP protocol with the SBP-Tag and the His-Tag, HDGF-protein complexes were purified using a TAP protocol with the SBP-Tag and with the FLAG-tag and Wnt complexes were purified using a TAP protocol with the SBP-Tag and with the [Calmodulin-Tag]. TAP is generally used with protein complexes and several studies report significant improvements in purity and yield when the SBP-Tag TAP systems are compared to non-SBP-Tag systems. Commercial TAP systems that use the SBP-Tag include the Interplay® Adenoviral and Mammalian TAP Systems sold by Agilent Technologies, similar products are sold by Sigma-Aldrich.
Chemical elements data references List of chemical elements – atomic mass, atomic number, symbol, name List of minerals – Minerals Electron configurations of the elements (data page) – electron configuration, electrons per shell Densities of the elements (data page) – density (solid, liquid, gas) Electron affinity (data page) – electron affinity Melting points of the elements (data page) – melting point Boiling points of the elements (data page) – boiling point Critical points of the elements (data page) – critical point Heats of fusion of the elements (data page) – heat of fusion Heats of vaporization of the elements (data page) – heat of vaporization Heat capacities of the elements (data page) – heat capacity Vapor pressures of the elements (data page) – vapor pressure Electronegativities of the elements (data page) – electronegativity (Pauling scale) Ionization energies of the elements (data page) – ionization energies (in eV) and molar ionization energies (in kJ/mol) Atomic radii of the elements (data page) – atomic radius (empirical), atomic radius (calculated), van der Waals radius, covalent radius Electrical resistivities of the elements (data page) – electrical resistivity Thermal conductivities of the elements (data page) – thermal conductivity Thermal expansion coefficients of the elements (data page) – thermal expansion Speeds of sound of the elements (data page) – speed of sound Elastic properties of the elements (data page) – Young's modulus, Poisson ratio, bulk modulus, shear modulus Hardnesses of the elements (data page) – Mohs hardness, Vickers hardness, Brinell hardness Abundances of the elements (data page) – Earth's crust, sea water, Sun and solar system List of oxidation states of the elements – oxidation states List of compounds List of CAS numbers by chemical compound List of Extremely Hazardous Substances List of inorganic compounds List of organic compounds List of alkanes List of alloys Other List of thermal conductivities List of purification methods in chemistry List of unsolved problems in chemistry
=== November === 1 November – The Commissioner for Ethical Standards in Public Life in Scotland finds SNP councillor Kairin van Sweeden in breach of the code of conduct for calling a political opponent a "New Scot" during a meeting of Aberdeen City Council in October 2023. 2 November – A 74-year-old man receives fatal injuries after being struck by a bus in Edinburgh's Cowgate. The following day, Police Scotland ask members of the public to stop sharing graphic images of the incident on social media. 3 November – Police Scotland say they have received a fresh allegation concerning a non-recent sexual assault against former First Minister Alex Salmond. 5 November – Senior consultants in Scotland have voted to accept a 10.5% pay rise that will see them earn between £10,500 and £13,500 extra each year, and which will be backdated to 1 April 2024. A waste management company is to sue the Scottish Government for £170m over the failed bottle return scheme. Bonfire Night disturbance breaks out in parts of Edinburgh, with missiles such as bricks, bottles and fireworks thrown at police. 6 November – Police Scotland say they have made 19 arrests following disturbances over Halloween and Bonfire Night. 8 November – The death certificate of Susan McGowan, a 58-year-old nurse from North Lanarkshire who died in September, has linked her death with the use of the weight loss drug tirzepatide (known under the brand name Mounjaro), which was recently approved for use on the NHS; it is reported to be the first UK death linked to the drug's use.
=== Pharmacodynamics === LGD-4033 is a selective androgen receptor modulator (SARM), or a tissue-selective mixed agonist or partial agonist of the androgen receptor (AR). This receptor is the biological target of endogenous androgens like testosterone and dihydrotestosterone (DHT) and of synthetic anabolic steroids like nandrolone and oxandrolone. LGD-4033 shows high affinity and selectivity for the AR, with an affinity (Ki) value of 0.9 nM. It did not meaningfully interact with the progesterone receptor, glucocorticoid receptor, or mineralocorticoid receptor (all Ki > 4,000 nM), whereas the estrogen receptor α was not assessed. In terms of in vitro transcriptional activity at the AR, the efficacy (Emax) of LGD-4033 was 132% to 133% and its EC50 was 3.6 to 4.4 nM. The AR is widely expressed in tissues throughout the body, including in the prostate gland, seminal vesicles, genitals, gonads, skin, hair follicles, muscle, bone, heart, adrenal cortex, liver, kidneys, and brain, among others. LGD-4033 has been found to have varying full agonist and partial agonist AR-mediated effects in different tissues, including potent agonistic and anabolic activity in muscle and bone and weaker partial agonist activity in the prostate gland and sebaceous glands. LGD-4033 has shown robust selectivity for stimulation of the levator ani muscle relative to stimulation of the prostate in rats.
=== Spray drug testing === Spray (sweat) drug test kits are non-invasive. It is a simple process to collect the required specimen, no bathroom is needed, no laboratory is required for analysis, and the tests themselves are difficult to manipulate and relatively tamper-resistant. The detection window is long and can detect recent drug use within several hours. There are also some disadvantages to spray or sweat testing. There is not much variety in these drug tests, only a limited number of drugs can be detected, prices tend to be higher, and inconclusive results can be produced by variations in sweat production rates in donors. They also have a relatively long specimen collection period and are more vulnerable to contamination than other common forms of testing.
Sources: en.wikipedia.org
The goal of Lost Coast was to demonstrate the new high-dynamic-range rendering implemented into the Source game engine. Valve first attempted to implement high-dynamic-range rendering in Source in late 2003. The first method stored textures in RGBA color space, allowing for multisample anti-aliasing and pixel shaders to be used, but this prevented alpha mapping and fog effects from working correctly, as well as making textures appear sharp and jagged. The second method involved saving two versions of a texture: one with regular data, and the other with overbrightening data. However, this technique did not allow for multisample anti-aliasing and consumed twice as much video card memory, making it infeasible. The third method, shown at the E3 convention in 2005, used floating-point data to define the RGB color space, allowing for reasonably efficient storage of the high-dynamic-range data. However, this method also did not allow for multisample anti-aliasing, and was only compatible with Nvidia video cards, leaving ATI cards unable to run high dynamic range. The fourth and final method compromised between the second and third methods, using overbrightening textures sparingly and allowing ATI cards to render HDR in a different way from the Nvidia ones while nearly producing the same result. The final version of Valve's high-dynamic-range technology adds a significant number of lighting effects to the engine, aimed at making the game appear more realistic. Bloom shading was introduced, blurring bright edges in the game world and emulating a camera's overexposure to light.
In accordance, studies of the amount of oral estradiol necessary for endometrial proliferation in women have reported a total dose of 60 mg for micronized estradiol relative to 120 to 300 mg or more for non-micronized estradiol. As such, micronization has been said to substantially improve the potency of oral estradiol.
Along the economic crisis, the other major problem that the government of Mariano Rajoy had to face was the "sovereigntist challenge" in Catalonia. The growth of Catalan independence after the Constitutional Court sentence on the Statute of Autonomy of Catalonia of 2006, which motivated a big rejection demonstration held in Barcelona on July 9, 2010, under the slogan Som una nació, nosaltres decidim, was clearly evidenced in the big demonstration organized in Barcelona, September 11, 2012, National Day of Catalonia, with the slogan Catalunya, nou estat d'Europa and organized by the self-styled Assemblea Nacional Catalana. Two weeks later the Parlament of Catalonia passed a resolution urging the government to hold a "consultation" in which "the people of Catalonia can freely and democratically determine their collective future." Following this, the president of the Generalitat Artur Mas brought forward by two years the elections to the Parliament of Catalonia scheduled for 2014 and these were held on November 25. Although CiU lost some deputies, both Esquerra Republicana and Iniciativa per Catalunya increased their parliamentary representation, and also the CUP entered the Parliament with three deputies, so that a "sovereigntist" majority was configured in the Parliament of Catalonia. Thus on January 23, 2013, the Parliament approved the "Declaration of Sovereignty and of the right to decide of the People of Catalonia" whose first article was annulled by the Constitutional Court the following year.
== LED light therapy v.s laser therapy == In the field of phototherapy, Low-Level Laser Therapy (LLLT) and LED Therapy (LEDT) are well-known modalities that provide non-invasive treatment options for a variety of medical conditions. Low-Level Laser Therapy (LLLT) employs low-intensity lasers, occasionally supplemented by LED lighting, to address a variety of medical conditions. Similar to LED Therapy (LEDT), LLLT's applications include the treatment of skin issues such as inflammation and pigmentation, tissue damage, and cardiovascular concerns. Although both LEDT and LLLT share therapeutic goals, LEDT is particularly noted for its cost-effectiveness and is designed for broader coverage using expansive LED panels, whereas LLLT utilizes more focused, coherent laser light for targeted areas. For this reason, laser therapy is appropriate for treating tissues beneath the hypodermis, LED therapy is more effective in treating cutaneous diseases.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.